K. Queen

发表

Development of [3H]nicotine binding sites in brain regions of rats exposed to nicotine prenatally via maternal injections or infusions.

T. Slotkin, L. Orband-Miller, K. Queen, 1987, The Journal of pharmacology and experimental therapeutics.

3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines: CCK-A agonists that demonstrate oral activity as satiety agents.

M. K. James, T. Willson, B. Henke, 1996, Journal of medicinal chemistry.

Optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists.

M. K. James, T. Willson, B. Henke, 1997, Journal of medicinal chemistry.

1,4-Benzodiazepine peripheral cholecystokinin (CCK-A) receptor agonists.

M. K. James, T. Rimele, R. G. Sherrill, 2001, Bioorganic & medicinal chemistry letters.

Constitutive receptor systems for drug discovery.

J. Way, W. J. Chen, D. Ignar, 1999, Journal of pharmacological and toxicological methods.

Beta adrenergic control of macromolecule synthesis in neonatal rat heart, kidney and lung: relationship to sympathetic neuronal development.

T. Slotkin, L. Orband-Miller, K. Queen, 1987, The Journal of pharmacology and experimental therapeutics.

Role of sympathetic neurons in biochemical and functional development of the kidney: neonatal sympathectomy with 6-hydroxydopamine.

R. Kavlock, T. Slotkin, A. Cameron, 1988, The Journal of pharmacology and experimental therapeutics.

Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity (II): Optimization of the C3 amino substituent.

M. K. James, T. Willson, B. Henke, 1996, Journal of medicinal chemistry.

Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger".

M. K. James, L. Miller, R. Carr, 1996, Journal of medicinal chemistry.

Use of constitutive G protein-coupled receptor activity for drug discovery.

J. Way, W. J. Chen, C. Jayawickreme, 2000, Molecular pharmacology.

Effects of prenatal nicotine exposure on biochemical development of rat brain regions: maternal drug infusions via osmotic minipumps.

T. Slotkin, K L Queen, F J Seidler, 1987, The Journal of pharmacology and experimental therapeutics.

Do sympathetic neurons coordinate cellular development in the heart and kidney? Effects of neonatal central and peripheral catecholaminergic lesions on cardiac and renal nucleic acids and proteins.

S. Stasheff, T. Slotkin, B. Levant, 1988, The Journal of pharmacology and experimental therapeutics.

Trophic control of lung development by sympathetic neurons: effects of neonatal sympathectomy with 6-hydroxydopamine.

R. Kavlock, T. Slotkin, A. Cameron, 1988, Journal of developmental physiology.

Biochemical Determinants of Growth Sparing during Neonatal Nutritional Deprivation or Enhancement: Ornithine Decarboxylase, Polyamines, and Macromolecules in Brain Regions and Heart

T. Slotkin, J. Bell, L. Orband-Miller, 1987, Pediatric Research.

Do catecholamines contribute to the effects of neonatal hypoxia on development of brain and heart? Influence of concurrent α-adrenergic blockade on ornithine decarboxylase activity

T. Slotkin, L. Orband-Miller, K. Queen, 1987, International Journal of Developmental Neuroscience.

Structure activity relationships of a series of buspirone analogs at alpha-1 adrenoceptors: further evidence that rat aorta alpha-1 adrenoceptors are of the alpha-1D-subtype.

A. Goetz, T. Rimele, M W Lutz, 1996, The Journal of pharmacology and experimental therapeutics.

Discovery of 1,5‐Benzodiazepines with Peripheral Cholecystokinin (CCK‐ A) Receptor Agonist Activity (II): Optimization of the C3 Amino Substituent.

T. Willson, B. Henke, J. Szewczyk, 1997 .

A mathematical model for analysis of pharmacologically induced changes in the kinetics of cardiac muscle.

T. Kenakin, A. Goetz, T. Rimele, 1996, Journal of pharmacological and toxicological methods.